Adam Andrzej Plich

CEO & Founder, Avanzanite Bioscience

[Avanzanite Bioscience @AvanzaniteBio]

“Together with my colleagues in Germany and Europe, we have a great opportunity and mission to significantly improve the lives of people with rare diseases.” https://t.co/stC5osqABT
#innovation #orphandrugs #raredisease #dRTA #nephrology #pediatricnephrology #pediatrics #kidney

[Adam Andrzej Plich @AdamPlich]

2023 Knights for Rare: The Acanthamoeba Keratitis Eye Foundation https://t.co/S4OylAekWc via @YouTube #raredisease

[Avanzanite Bioscience @AvanzaniteBio]

Today is #rarediseaseday and we are excited to share that we've partnered with #Advicenne in distal Renal Tubular Acidosis (#dRTA).

https://t.co/ydAlKNCSDS

#raredisease #patientsfirst #orphandrugs

[Adam Andrzej Plich @AdamPlich]

READ more about our partnership with SIFI in #acanthamoebakeratitis #RareDiseases #orphandrugs #innovation #patientsfirst
https://t.co/lZ9YN1YNoU

[Adam Andrzej Plich @AdamPlich]

Read about Avanzanite in the latest issue of @Biotech_finance #orphandrugs #raredisease #patientaccess #innovation

[Adam Andrzej Plich @AdamPlich]

Avanzanite Bioscience looks to commercialize innovative medicines for rare diseases in Europe https://t.co/70MKpUZOJX via @Labiotech_eu #rarediseases #orphandrugs #innovation

[Adam Andrzej Plich @AdamPlich]

BRIEF—New business model to boost orphan drug access in Europe https://t.co/Vor1peRrBq #orphandrugs #rarediseases #corporatelaunch #innovation #energy

[Adam Andrzej Plich @AdamPlich]

We are providing a market-driven solution for the issue of access to orphan medicines in Europe. https://t.co/sNAfI8bocA

[Adam Andrzej Plich @AdamPlich]

We are on a mission to redefine the #orphandrug landscape. We expand #patientaccess to medicines for #rarediseases while unlocking revenue & growth for emerging research-based #biopharmaceutical partners – through flexible, bespoke licensing & distribution partnerships across EU.

[Adam Andrzej Plich @AdamPlich]

Launching Avanzanite Bioscience Today – Find out WHY: https://t.co/sUrJmGWNAh
#orphandrugs #rarediseases #patientaccess
#innovation #corporatelaunch